Regencell Bioscience Holdings Ltd

# Regencell Bioscience Holdings Ltd

Regencell Bioscience operates as a Traditional Chinese medicine (TCM) bioscience company focused on research and development of therapeutic treatments for neurocognitive disorders. The company's primary development areas include attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), applying TCM principles and methodologies to address these conditions. Founded in 2014 and incorporated in the Cayman Islands, the company maintains headquarters in Causeway Bay, Hong Kong, with operations positioned within Asia's regulatory framework for biologics and specialty pharmaceuticals.

The company operates within the specialty and generic drug manufacturing sector, with its business model centered on the development and commercialization of TCM-based bioscience products. The specific revenue composition and distribution across product lines or geographic markets remains limited in available disclosures. Operating with a small workforce of 10 full-time employees, Regencell represents a development-stage biotech entity with a concentrated research focus rather than a large-scale manufacturing or commercial operation.